Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

医学 转移性乳腺癌 结合 阿霉素 乳腺癌 癌症 肿瘤科 内科学 化疗 数学 数学分析
作者
Anthony W. Tolcher,Steven Sugarman,Karen A. Gelmon,Roger Cohen,Mansoor N. Saleh,Claudine Isaacs,Leslie Young,Diane Healey,Nicole Onetto,William J. Slichenmyer
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:17 (2): 478-478 被引量:262
标识
DOI:10.1200/jco.1999.17.2.478
摘要

PURPOSE: BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules. The antibody is directed against the Lewis-Y antigen, which is expressed on 75% of all breast cancers but is limited in expression on normal tissues. Preclinical xenograft models demonstrated significant antitumor activity, including cures. A randomized phase II design was chosen to estimate the activity of the BR96-doxorubicin conjugate in metastatic breast cancer in a study population with confirmed sensitivity to single-agent doxorubicin. PATIENTS AND METHODS: Patients with measurable metastatic breast cancer and immunohistochemical evidence of Lewis-Y expression on their tumor received either BR96-doxorubicin conjugate 700 mg/m 2 IV over 24 hours or doxorubicin 60 mg/m 2 every 3 weeks. Patients were stratified on the basis of prior doxorubicin exposure, visceral disease, and institution. Cross-over to the opposite treatment arm was allowed with progressive or persistently stable disease. RESULTS: Twenty-three patients who had received a median of one prior chemotherapy regimen were assessable. There was one partial response (7%) in 14 patients receiving the BR96-doxorubicin conjugate and one complete response and three partial responses (44%) in nine assessable patients receiving doxorubicin. No patient experienced a clinically significant hypersensitivity reaction. The toxicities were significantly different between the two treatment groups, with the BR96-doxorubicin conjugate group having limited hematologic toxicity, whereas gastrointestinal toxicities, including marked serum amylase and lipase elevations, nausea, and vomiting with gastritis, were prominent. CONCLUSION: The BR96-doxorubicin immunoconjugate has limited clinical antitumor activity in metastatic breast cancer. The gastrointestinal toxicities likely represent binding of the agent to normal tissues expressing the target antigen and may have compromised the delivery of the immunoconjugate to the tumor sites.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
烟花应助冷艳如柏采纳,获得10
1秒前
1秒前
大个应助陈俊辉采纳,获得10
1秒前
2秒前
2秒前
拉拉霍霍发布了新的文献求助10
2秒前
Cc完成签到,获得积分10
2秒前
3秒前
haowu发布了新的文献求助20
3秒前
领导范儿应助MQRR采纳,获得10
3秒前
5秒前
敏子完成签到,获得积分10
5秒前
twenty完成签到 ,获得积分10
6秒前
yxt发布了新的文献求助10
6秒前
重要的又亦完成签到 ,获得积分10
6秒前
无奈的映波完成签到,获得积分20
7秒前
自信寒蕾发布了新的文献求助10
7秒前
拉拉霍霍完成签到,获得积分10
9秒前
研友_nv4Bx8完成签到,获得积分10
11秒前
花佚狐完成签到,获得积分10
11秒前
12秒前
12秒前
Cyber_relic完成签到,获得积分10
13秒前
孤独的慕蕊完成签到,获得积分10
14秒前
15秒前
JamesPei应助自信寒蕾采纳,获得10
15秒前
16秒前
巴啦啦能量完成签到 ,获得积分10
17秒前
ding应助Noah采纳,获得10
17秒前
19秒前
陈俊辉发布了新的文献求助10
19秒前
酒石酸完成签到,获得积分10
19秒前
zhao发布了新的文献求助10
19秒前
墩子完成签到,获得积分10
19秒前
19秒前
唐少北发布了新的文献求助30
20秒前
20秒前
22秒前
守仁则阳明完成签到 ,获得积分10
22秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 830
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3247916
求助须知:如何正确求助?哪些是违规求助? 2891121
关于积分的说明 8266358
捐赠科研通 2559345
什么是DOI,文献DOI怎么找? 1388162
科研通“疑难数据库(出版商)”最低求助积分说明 650698
邀请新用户注册赠送积分活动 627590